PEPTIDES & PROTEINS
and scanning electron microscopy with energy-dispersive X-ray spectroscopy( SEM-EDX) on isolated particles can, for example, differentiate silicone oil droplets, glass or metal fragments, elastomers and peptidederived particulates.
From a risk perspective, particulate matter deserves explicit attention. Even within limits, shifts in particle morphology or identity can flag packaging or process issues before visible defects occur. Combining counting with orthogonal imaging and identification therefore supports both patient safety and manufacturing control. Maintaining reference images and spectra helps standardise investigations and accelerate root-cause work.
While particulate control addresses physical stability across multiple size regimes, chemical degradation pathways require parallel attention with orthogonal analytical readouts tailored to the peptide ' s sequence and formulations.
Chemical stability
Assessing chemical stability requires methods capable of identifying observed impurities to support investigation and mitigation. For many peptides, a tiered approach is efficient:
• Tier 1( routine trending): RP-HPLC or UPLC for assay and purity, with an orthogonal separation( ionexchange chromatography or capillary electrophoresis) where charge variants are expected
• Tier 2( impurity identification): LC – MS for intact mass and targeted characterisation to identify oxidation sites, deamidation, clipping and other modifications, ensuring that‘ new peaks’ have a defensible identity
• Tier 3( conformational readouts): Circular dichroism( CD), FTIR, and differential scanning calorimetry( DSC) to detect structural changes that may precede aggregation or potency loss, particularly for peptides with defined secondary structure or engineered constraints
Where deeper structural questions arise, additional tools such as NMR, fibrillation assays( e. g., thioflavin-T) or hydrogen – deuterium exchange MS can be deployed hypothesis-driven to confirm specific mechanisms.
Interpreting chemical and physical trends together is often decisive. Increases in hydrophobic impurities( oxidation) may co-vary with aggregation signals, charge variants can shift self-association and trace-metal catalysis can drive both oxidation and particle formation.
Analytical data, whether purity trends, aggregate levels, or particle counts, gain clinical meaning when linked to functional readouts. Product-specific bioassays provide this translation layer.
A stability package is strongest when observed shifts in analytical readouts( CQAs) are linked to functional impact. Where feasible, product-specific bioassays( cell-based or binding assays, Figure 6) translate purity, identity and aggregation data into potency trends and can help prioritise which degradation pathways are clinically relevant.
Defensible control strategy
An orthogonal strategy is not a catalogue of techniques. It is a structured plan that:
• Starts with a risk assessment( sequence liabilities, intended concentration and route, container / device, expected stresses in manufacturing and shipping)
• Pairs each high-risk failure mode with at least two independent analytical principles( e. g. SEC plus SV-AUC for soluble aggregates, LO plus MFI for sub-visible particles, HPLC plus LC – MS for chemical degradants)
• Defines investigation triggers and escalation paths( e. g. a move from particle counting to particle ID when excursions occur)
• Integrates data handling and acceptance criteria setting( including trending rules and how analytical outputs drive formulation optimisation); and
• Anticipates the lifecycle: early screening, clinical comparability
and late-phase and post-approval change management
When working with contract laboratories, sponsors can improve study efficiency and regulatory clarity by specifying orthogonal method sets based on risk assessment and decision points, rather than requesting comprehensive method catalogues. This risk-based approach produces clearer narratives around degradation pathways and particulate control, because key conclusions rest on independent analytical principles rather than a single technique.
Conclusion
Peptide therapeutic stability is irreducibly multi-dimensional: chemical, colloidal, and particulate degradation pathways operate in parallel and often reinforce one another.
Robust development therefore requires orthogonal analytical methods spanning the nanometre-to-millimetre continuum, paired with decisionled study designs that align stress conditions and endpoints to programme risk. A risk-based strategy designed around mechanisms and decision points reduces late-stage surprises while providing the evidential depth expected for injectable products. ●
J j
Dr Achim Link
FIELD DEVELOPMENT MANAGER
SOLVIAS achim. link @ solvias. com www. solvias. com
38 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981